Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary antibody-drug ...

Andrew Bloomenthal has 20+ years of editorial experience as a financial journalist and as a financial services marketing writer. David Kindness is a Certified Public Accountant (CPA) and an expert in ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Find the latest China Development Bank International Investment Limited (1062.HK) stock quote, history, news and other vital information to help you with your stock trading and investing.

NOTE: Not all collection methods are supported on MySQL/MariaDB < 5.6 NOTE: It is recommended to set a max connection limit for the user to avoid overloading the server with monitoring scrapes under ...